Chronic Migraine Clinical Trial
Official title:
A Pilot Study to Evaluate the Efficacy of Intranasal K.O.S in the Preventive Treatment of Chronic Migraine on Patients Not Responding to a Treatment With Monoclonal Antibodies Targeting the CGRP Pathway.
NCT number | NCT05273151 |
Other study ID # | PM009 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | December 4, 2023 |
Est. completion date | June 15, 2025 |
An open pilot study, non-controlled, single center investigation.
Status | Recruiting |
Enrollment | 30 |
Est. completion date | June 15, 2025 |
Est. primary completion date | December 31, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion Criteria 1. The subject is legally competent, has been informed of the nature, the scope and the relevance of the study, voluntarily agrees to participation and the study's provisions, and has duly signed the informed consent form. 2. Male or female aged between 18 and 70 years (inclusive) at the time of providing informed consent. 3. Diagnosed as suffering from chronic migraine with or without aura (=15 headache days per month including at least 8 migraine days for more than 3 months before screening) according to the International Headache Society classification (International Classification of Headache Disorders III); 4. Migraine onset before the age of 50 years. 5. Reported history of migraine for at least 1 year before screening. 6. If subjects are on a preventive treatment at the time of screening, this must have been stable over the preceding 3 months. 7. If subjects are on preventive treatment at the time of screening, they have to be able and willing to maintain current preventive treatment regimen (no change in type, frequency or dose) from screening to end of follow- 8. Failed at least 3 different preventive medications and 3 months of treatment with a monoclonal antibody targeting the CGRP pathway. 9. Women of childbearing potential must be willing to use highly effective contraceptive methods (failure rate <1% per year when used consistently and correctly) during the study. Exclusion Criteria 1. Unable to distinguish between migraine and other headache types. 2. An ongoing upper respiratory infection, nasal tumors, or wounds in the nasal cavity. 3. Nasal cavity abnormalities that prevents catheter insertion. 4. A concomitant condition that could cause excessive nose bleeding or ongoing treatment with anticoagulant medication (except Aspirin and Clopidogrel). 5. A known allergy to polyurethane (polyurethane is used in the catheter balloon). 6. Systemic diseases with manifestations in the nose. 7. Previous treatment with radiation therapy to the nasal area. 8. Nasal surgery performed within the last six months. 9. Concurrent condition or risk of non-compliance that, in the investigator's opinion, may affect the interpretation of performance or safety data or which otherwise contraindicates participation in a clinical investigation; 10. Pregnant and lactating women; 11. Participation in a clinical investigation within 3 months of enrolment or planned participation at any time during this clinical investigation; 12. Previous participation in this study; 13. Employees of the study site or the sponsor directly involved with the conduct of the study, or immediate family members of any such individuals; |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Wolfson Centre for Age-Related Diseases Institute of Psychiatry, Psychology and Neuroscience Wellcome Foundation Building, Denmark Hill Campus King's College | London |
Lead Sponsor | Collaborator |
---|---|
Chordate Medical |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Mean change in headache days | Change in headache days with moderate to severe intensity after 6 weeks of treatment. Headache days are collected in eDiary | baseline to 6 weeks | |
Secondary | Mean change in Migraine days Mean change of migraine days, responder rate, use of abortive medication, health-related quality of life and disability, and patient's global impression of severity 12 weeks (90 days) | Migraine days is collected in an eDiary. | Baseline to 12 weeks | |
Secondary | Incidence of adverse events (AEs) and adverse device effects (ADEs) | All adverse events (AEs) and adverse device effects (ADEs) incidence and severity following treatment with the Chordate System 220 | Baseline to 12 weeks | |
Secondary | Number of patients who are responders | Responders are classified as responder (less migraine/headache days) or non-responder (same or worsening of migraine/headache days).
A respondes is a patient who has decrease of headaches/migraine days whilst a non responder had no or the same number of headache/migraine days |
baseline to 12 weeks | |
Secondary | Number of patients who decrease use of abortive medication | Intake of abortive medications are registred in eDiary and will be calculated on patient level | baseline to 12 weeks | |
Secondary | Mean change in Hospital Anxiety and Depression Scale (HADS) | HADS is a scale with 7 questions related to anxiety and 7 questions related to depression Anxiety can have 0-21 points (lower score means no anxiety) and Depression 0-21 points (higher score means no depression) | baseline to 12 weeks | |
Secondary | Mean change in Headache Impact Test (HIT-6) | HIT-6 consist of 6 questions HIT-6 with scores from 6 to 13 where 13 is worst case per question so lower score means less problems | baseline to 12 weeks | |
Secondary | Mean change in Subject global severity | Patient Global severity is a scale with four (4) scores, where normal (0) is the lowest and show no problems whilst severe (3) is the worst score 0=Normal
Mild Moderate Severe |
baseline to 12 weeks | |
Secondary | Mean change in headache days | Change in headache days with moderate to severe intensity from eDiary | week 6-12 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05720819 -
Biofeedback-VR for Treatment of Chronic Migraine
|
N/A | |
Not yet recruiting |
NCT06428838 -
Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency Context
|
Phase 3 | |
Recruiting |
NCT05517200 -
Pilot Study for a Machine Learning Test for Migraine
|
||
Recruiting |
NCT05891808 -
miR-155 Expression in Episodic and Chronic Migraine
|
||
Completed |
NCT02514148 -
Biobehavioral Physical Therapy Strategies Based on Therapeutic Exercise Applied to Chronic Migraine Patients
|
N/A | |
Enrolling by invitation |
NCT02291380 -
A Study to Evaluate Botulinum Toxin Type A for Injection(HengLi®)for Prophylactic Treatment of Chronic Migraine
|
Phase 3 | |
Withdrawn |
NCT02122744 -
RCT Versus Placebo of rTMSQP Over Visual Cortex for the Prevention of Chronic Migraine
|
N/A | |
Completed |
NCT02122237 -
Cathodal tDCS in Chronic Migraine: Neurophysiological Study and Pilot Therapeutic Trial
|
Phase 3 | |
Recruiting |
NCT02202486 -
Investigation of the Blood-brain and Blood-dura Barrier Durin Migraine Attacks Using MRI
|
N/A | |
Completed |
NCT01709708 -
Use of the Tx360 Nasal Applicator in the Treatment of Chronic Migraine
|
Phase 4 | |
Completed |
NCT01741246 -
Neuroimaging Studies of Chronic Primary Headaches Using Positron Emission Tomography and Magnetic Resonance Imaging
|
N/A | |
Completed |
NCT01090050 -
Treximet in the Treatment of Chronic Migraine
|
Phase 4 | |
Recruiting |
NCT03507400 -
Introvision for Migraine and Headaches
|
N/A | |
Completed |
NCT04161807 -
Efficacy and Safety of Nerivio™ for Acute Treatment of Migraine in People With Chronic Migraine
|
N/A | |
Completed |
NCT03175263 -
OnabotulinumtoxinA Injections in Chronic Migraine, Targeted to Sites of Pericranial Myofascial Pain
|
N/A | |
Withdrawn |
NCT04353505 -
Intra-arterial Sphenopalatine Ganglion Block for Patients With Refractory Headache
|
Phase 1 | |
Completed |
NCT01667250 -
Non-Invasive Neurostimulation for the Prevention of Chronic Migraine
|
N/A | |
Completed |
NCT01700387 -
A Study to Evaluate the Tolerability of Botox and Topiramate or Botox and Placebo and Effect on Cognitive Efficiency
|
Phase 4 | |
Not yet recruiting |
NCT01135784 -
Study of MIGRA-ZEN RELIEF PLUS In the Treatment of Chronic Migraine Headache
|
Phase 2 | |
Completed |
NCT01496950 -
Double-blind Randomized Clinical Trial of Transcranial Magnetic Stimulation in Chronic Migraine
|
Phase 1 |